Granting immunity to FOP and catching heterotopic ossification in the Act

Frederick S. Kaplan, Robert Pignolo, Eileen M. Shore

Research output: Contribution to journalReview article

29 Citations (Scopus)

Abstract

The progressive transformation of one organ system into another is a fundamental signature of fibrodysplasia ossificans progressiva (FOP), the most catastrophic form of extraskeletal bone formation in humans. In all affected individuals, FOP is caused by heterozygous missense gain-of-function mutations in Activin receptor A type I (ACVR1), a bone morphogenetic protein (BMP) type I receptor. Loss of autoinhibition of the mutant receptor (mACVR1) results in dysregulated BMP pathway signaling, and is necessary for the myriad developmental features of FOP, but does not appear sufficient to induce the episodic flare-ups that lead to disabling post-natal heterotopic endochondral ossification (HEO) and that are a hallmark of the disease. Post-natal FOP flare-ups strongly implicate an underlying immunological trigger involving inflammation and the innate immune system. Recent studies implicate canonical and non-canonical TGFβ/BMP family ligands in the amplification of mACVR1 signaling leading to the formation of FOP lesions and resultant HEO. BMP and Activin ligands that stimulate mACVR1 signaling also have critical regulatory functions in the immune system. Cross-talk between the morphogenetic and immunological pathways that regulate tissue maintenance and wound healing identifies potential robust therapeutic targets for FOP. Here we review current evidence for an immunological trigger for flare-ups and HEO in FOP, propose a working schema for the pathophysiology of observed phenomena, and highlight outstanding questions under investigation.

Original languageEnglish (US)
Pages (from-to)30-36
Number of pages7
JournalSeminars in Cell and Developmental Biology
Volume49
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Fingerprint

Myositis Ossificans
Heterotopic Ossification
Immunity
Osteogenesis
Bone Morphogenetic Proteins
Type I Activin Receptors
Immune System
Type I Bone Morphogenetic Protein Receptors
Ligands
Activins
Wound Healing
Maintenance
Inflammation
Mutation

Keywords

  • Activin A
  • ACVR1
  • Bone morphogenetic protein (BMP)
  • Bone morphogenetic protein signaling
  • Fibrodysplasia ossificans progressiva (FOP)
  • Heterotopic ossification
  • Innate immune system
  • Toll-like receptor (TLR)

ASJC Scopus subject areas

  • Developmental Biology
  • Cell Biology

Cite this

Granting immunity to FOP and catching heterotopic ossification in the Act. / Kaplan, Frederick S.; Pignolo, Robert; Shore, Eileen M.

In: Seminars in Cell and Developmental Biology, Vol. 49, 01.01.2016, p. 30-36.

Research output: Contribution to journalReview article

@article{e1bf210dfde2447aab3b0df40138599a,
title = "Granting immunity to FOP and catching heterotopic ossification in the Act",
abstract = "The progressive transformation of one organ system into another is a fundamental signature of fibrodysplasia ossificans progressiva (FOP), the most catastrophic form of extraskeletal bone formation in humans. In all affected individuals, FOP is caused by heterozygous missense gain-of-function mutations in Activin receptor A type I (ACVR1), a bone morphogenetic protein (BMP) type I receptor. Loss of autoinhibition of the mutant receptor (mACVR1) results in dysregulated BMP pathway signaling, and is necessary for the myriad developmental features of FOP, but does not appear sufficient to induce the episodic flare-ups that lead to disabling post-natal heterotopic endochondral ossification (HEO) and that are a hallmark of the disease. Post-natal FOP flare-ups strongly implicate an underlying immunological trigger involving inflammation and the innate immune system. Recent studies implicate canonical and non-canonical TGFβ/BMP family ligands in the amplification of mACVR1 signaling leading to the formation of FOP lesions and resultant HEO. BMP and Activin ligands that stimulate mACVR1 signaling also have critical regulatory functions in the immune system. Cross-talk between the morphogenetic and immunological pathways that regulate tissue maintenance and wound healing identifies potential robust therapeutic targets for FOP. Here we review current evidence for an immunological trigger for flare-ups and HEO in FOP, propose a working schema for the pathophysiology of observed phenomena, and highlight outstanding questions under investigation.",
keywords = "Activin A, ACVR1, Bone morphogenetic protein (BMP), Bone morphogenetic protein signaling, Fibrodysplasia ossificans progressiva (FOP), Heterotopic ossification, Innate immune system, Toll-like receptor (TLR)",
author = "Kaplan, {Frederick S.} and Robert Pignolo and Shore, {Eileen M.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/j.semcdb.2015.12.013",
language = "English (US)",
volume = "49",
pages = "30--36",
journal = "Seminars in Cell and Developmental Biology",
issn = "1084-9521",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Granting immunity to FOP and catching heterotopic ossification in the Act

AU - Kaplan, Frederick S.

AU - Pignolo, Robert

AU - Shore, Eileen M.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The progressive transformation of one organ system into another is a fundamental signature of fibrodysplasia ossificans progressiva (FOP), the most catastrophic form of extraskeletal bone formation in humans. In all affected individuals, FOP is caused by heterozygous missense gain-of-function mutations in Activin receptor A type I (ACVR1), a bone morphogenetic protein (BMP) type I receptor. Loss of autoinhibition of the mutant receptor (mACVR1) results in dysregulated BMP pathway signaling, and is necessary for the myriad developmental features of FOP, but does not appear sufficient to induce the episodic flare-ups that lead to disabling post-natal heterotopic endochondral ossification (HEO) and that are a hallmark of the disease. Post-natal FOP flare-ups strongly implicate an underlying immunological trigger involving inflammation and the innate immune system. Recent studies implicate canonical and non-canonical TGFβ/BMP family ligands in the amplification of mACVR1 signaling leading to the formation of FOP lesions and resultant HEO. BMP and Activin ligands that stimulate mACVR1 signaling also have critical regulatory functions in the immune system. Cross-talk between the morphogenetic and immunological pathways that regulate tissue maintenance and wound healing identifies potential robust therapeutic targets for FOP. Here we review current evidence for an immunological trigger for flare-ups and HEO in FOP, propose a working schema for the pathophysiology of observed phenomena, and highlight outstanding questions under investigation.

AB - The progressive transformation of one organ system into another is a fundamental signature of fibrodysplasia ossificans progressiva (FOP), the most catastrophic form of extraskeletal bone formation in humans. In all affected individuals, FOP is caused by heterozygous missense gain-of-function mutations in Activin receptor A type I (ACVR1), a bone morphogenetic protein (BMP) type I receptor. Loss of autoinhibition of the mutant receptor (mACVR1) results in dysregulated BMP pathway signaling, and is necessary for the myriad developmental features of FOP, but does not appear sufficient to induce the episodic flare-ups that lead to disabling post-natal heterotopic endochondral ossification (HEO) and that are a hallmark of the disease. Post-natal FOP flare-ups strongly implicate an underlying immunological trigger involving inflammation and the innate immune system. Recent studies implicate canonical and non-canonical TGFβ/BMP family ligands in the amplification of mACVR1 signaling leading to the formation of FOP lesions and resultant HEO. BMP and Activin ligands that stimulate mACVR1 signaling also have critical regulatory functions in the immune system. Cross-talk between the morphogenetic and immunological pathways that regulate tissue maintenance and wound healing identifies potential robust therapeutic targets for FOP. Here we review current evidence for an immunological trigger for flare-ups and HEO in FOP, propose a working schema for the pathophysiology of observed phenomena, and highlight outstanding questions under investigation.

KW - Activin A

KW - ACVR1

KW - Bone morphogenetic protein (BMP)

KW - Bone morphogenetic protein signaling

KW - Fibrodysplasia ossificans progressiva (FOP)

KW - Heterotopic ossification

KW - Innate immune system

KW - Toll-like receptor (TLR)

UR - http://www.scopus.com/inward/record.url?scp=84958104294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958104294&partnerID=8YFLogxK

U2 - 10.1016/j.semcdb.2015.12.013

DO - 10.1016/j.semcdb.2015.12.013

M3 - Review article

VL - 49

SP - 30

EP - 36

JO - Seminars in Cell and Developmental Biology

JF - Seminars in Cell and Developmental Biology

SN - 1084-9521

ER -